Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 12—December 2025

Research Letter

Carbapenem-Resistant Salmonella Typhi Infection in Traveler Returning to Germany from India, 2024

Sandra Simon, Eva Trost, Jan Lennings, Julia Enkelmann, Julia Kuhn, Michael Pietsch, and Antje FliegerComments to Author 
Author affiliation: Robert Koch Institute, Wernigerode, Germany (S. Simon, E. Trost, M. Pietsch, A. Flieger); Public Health Department of Stuttgart, Stuttgart, Germany (J. Lennings); Robert Koch Institute, Berlin, Germany (J. Enkelmann); Ministry of Social Affairs, Health and Integration Baden-Wuerttemberg, Stuttgart (J. Kuhn)

Main Article

Table

Antimicrobial-resistance profiles and corresponding genetic determinants of isolate 24-09143 froma traveler returning to Germany from India in comparison to selected published Salmonella Typhi genomes from Pakistan and India*

Antimicrobial
class or substance		 Genome and applied substance panel
24-09143 Germany 2024,† carbapenemase+, ESBL+
 1790125 Pakistan 2022,‡ XDR+, carbapenemase+, ESBL+
 Gurgaon01 India 2019,§ ESBL+
 IOB-SWH-1 India 2024,# carbapenemase+
MIC, mg/L Gene or mutation MIC, mg/L Gene or mutation MIC, mg/L or DD, mm Gene or mutation MIC, mg/L or DD, mm Gene or mutation
Penicillins
Ampicillin
 >32
 blaNDM-5
32
 blaNDM-5, blaTEM-1
>256
 blaTEM-1
>32
 blaNDM-5
Cephalosporins
Cefotaxime >8 blaNDM-5, blaCTX-M-15 64 blaNDM-5, blaCTX-M-15 NS blaCTX-M-15 NS blaNDM-5
Ceftazidime >8 128 >256 NS
Cefoxitin† >32 64 NS NS
Ceftriaxon
 NS
NS
>256
>64
Quinolones
Ciprofloxacin 2 gyrA_S83Y, qnrS1 64 gyrA_S83F, qnrS1 2 gyrA_S83Y, qnrS1 >4 gyrA_S83Y
Nalidixic acid¶
 >32
8
DD 6 mm
NS
Carbapenems
Meropenem
 >16
 blaNDM-5
16
 blaNDM-5
0.023
 NS
>16
 blaNDM-5
Macrolides
Azithromycin¶
 2
 NS
64
 mphA
8
 NS
6
 NS
Phenicols
Chloramphenicol¶
 4
 NS
64
 catA
DD 28 mm
 NS
DD (susceptible)
 NS
Tetracyclines¶ >32 tet(A) 32 tet(A) 64 tet(A) NS NS
Sulfonamides¶ NS NS 512 sul-1 NS sul-2 NS NS
Trimethoprim 0.5 NS 16 dfrA-27, dfrA-7 NS dfrA14 NS NS
Sulfamethoxazole/trimethoprim <0.25 NS NS sul-1, dfrA-27, dfrA-7 >256 sul-2, dfrA14 <20 NS

*Bold indicates resistance. DD, disk diffusion assay; ENA, European Nucleotide Archive; ESBL, extended-spectrum β-lactamase; NS, not specified; XDR, extensively drug-resistant; +, positive. †ENA accession no. ERR15390137. ‡ENA accession no. SRR22801766. §ENA accession no. ERR3527963. #ENA accession no. SRR32461882. ¶No clinical breakpoints defined by European Committee on Antimicrobial Susceptibility Testing.

Main Article

Page created: December 11, 2025
Page updated: December 23, 2025
Page reviewed: December 23, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external